Zbyněk Bortlíček

Medicine · Health Sciences

19h-index1.2kcitations193works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(45), Multiple and Secondary Primary Cancers(36), Colorectal Cancer Treatments and Studies(27), Lung Cancer Research Studies(18), Renal cell carcinoma treatment(17)

Publications193 total

Centrová léčba nemalobuněčného karcinomu plic (NSCLC) v ČR vroce 2021
2021
The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL)
Annals of Hematology·2020
First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients
Annals of Hematology·2019· 33 cited
Outlier cases detection in diagnoses-related group system using prediction intervals of various parametric distributions
2019
Calculation of cost-related severity of secondary diagnoses and inpatient cases within the DRG classification system
2019
Tyrosine-kinase inhibitors (TKI) in first-line treatment of patients with non-small cell lung cancer (NSCLC) - real life data from the Czech Republic
Lung Cancer·2018
The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database
Annals of Hematology·2018· 15 cited
Možnosti diagnostiky revmatické polymyalgie a obrovskobuněčné arteritidy pomocí FDG PET a PET/CT zobrazení-dvanáctileté zkušenosti jednoho diagnostického centra.
2018
Analýza klinických a epidemiologických dat: od přípravy dat až po vizualizaci výsledků
Munispace – čítárna Masarykovy univerzity·2018
Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry
BMC Cancer·2017· 11 citedOpen Access
P2.03-023 Characteristics of NSCLC Patients Treated in First Line Treatment with Tyrosine Kinase Inhibitors (TKI) - Real Data from the Czech Republic
Journal of Thoracic Oncology·2017· 1 citedOpen Access
Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer
Clinical Genitourinary Cancer·2017· 9 cited
Locally advanced breast cancer in elderly patients
Biomedical Papers·2017· 13 citedOpen Access
Comparing Clinical Characteristics and Outcomes of Young-onset and Late-onset Colorectal Cancer: An International Collaborative Study
Clinical Colorectal Cancer·2017· 66 cited
Abstract P4-21-12: Preference of trastuzumab administration route (intravenous or subcutaneous) in patients in the Czech Republic. Cross-sectional study on 429 patients
Cancer Research·2017· 1 cited
PET/CT imaging in polymyalgia rheumatica: praepubic <sup>18</sup>F-FDG uptake correlates with pectineus and adductor longus muscles enthesitis and with tenosynovitis
Radiology and Oncology·2017· 16 citedOpen Access
CHARAKTERISTIKY PACIENTŮ S NSCLC A AKTIVAČNÍMI MUTACEMI EGFR LÉČENÝCH INHIBITORY TYROZINKINÁZY PO STANOVENÍ DIAGNÓZY - REÁLNÁ DATA Z ČESKÉ REPUBLIKY
2017
Jak používáme v České republice inhibitory tyrozinkinázy (TKI) po stanovení diagnózy u pacientů s NSCLC
2017
Léčba pokročilého nemalobuněčného karcinomu plic (NSCLC) v ČR v roce 2017 (aktuální stav, výhled do budoucna)
2017
P3.02b-082 Gefitinib in First-Line Treatment of Caucasian Patients with NSCLC and EGFR Mutations in Exons 19 or 21
Journal of Thoracic Oncology·2017
page 1 of 10Next →

Frequent Co-authors

Tomáš Büchler(22), Ondřej Fiala(21), Bohuslav Melichar(18), Jindřich Fínek(18), Rostislav Vyzula(17), Ladislav Dušek(15), Alexandr Poprach(14), Miloš Pešek(12), Marek Minárik(12), Tomáš Pavlík(11), Ondřej Topolčan(11), Lucie Benešová(11), Igor Kišš(11), Marek Svoboda(9), Kateřina Kubáčková(7), Radek Lakomý(7), Jana Prausová(6), Milada Zemanová(6), Ondřej Slabý(5), Martin Svatoň(5)